FOURIER (TIMI 59) / EBBINGHAUS

FOURIER (TIMI 59) is a double-blind, randomized, placebo-controlled, multicenter study assessing the Impact of additional LDL-cholesterol reduction on major cardiovascular events when AMG 145 is used in combination with statin therapy in patients with clinically evident cardiovascular disease.

EBBINGHAUS is a cognitive study of patients enrolled in the FOURIER trial.

FOURIER Slide Set

EBBINGHAUS Slide Set

BWH Cardiovascular Grand Rounds - April 6, 2017

NLA 2017 - May 5, 2017

Key Study Publications

Sabatine MS,  Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SW, Sever PS, Pedersen TR. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. 2017 NEJM, Epub before print. 

LINK TO CLINICALTRIALS.GOV